MA33142B1 - Mutants fgf21 et leurs utilisations - Google Patents
Mutants fgf21 et leurs utilisationsInfo
- Publication number
- MA33142B1 MA33142B1 MA34197A MA34197A MA33142B1 MA 33142 B1 MA33142 B1 MA 33142B1 MA 34197 A MA34197 A MA 34197A MA 34197 A MA34197 A MA 34197A MA 33142 B1 MA33142 B1 MA 33142B1
- Authority
- MA
- Morocco
- Prior art keywords
- polypeptides
- mutant
- fgf21
- fgf21 mutants
- pharmaceutical compositions
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title abstract 5
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/05—Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
L'invention porte sur des molécules d'acide nucléique codant pour des polypeptides mutants FGF21, sur des polypeptides mutants FGF21, sur des compositions pharmaceutiques comprenant des polypeptides mutants FGF21, et sur des procédés pour traiter des troubles métaboliques à l'aide de tels acides nucléiques, de tels polypeptides ou de telles compositions pharmaceutiques.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5886108P | 2008-06-04 | 2008-06-04 | |
US5891908P | 2008-06-04 | 2008-06-04 | |
US16436409P | 2009-03-27 | 2009-03-27 | |
US17573609P | 2009-05-05 | 2009-05-05 | |
PCT/US2009/046113 WO2009149171A2 (fr) | 2008-06-04 | 2009-06-03 | Mutants fgf21 et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33142B1 true MA33142B1 (fr) | 2012-03-01 |
Family
ID=40984291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34197A MA33142B1 (fr) | 2008-06-04 | 2009-06-03 | Mutants fgf21 et leurs utilisations |
Country Status (23)
Country | Link |
---|---|
US (9) | US8034770B2 (fr) |
EP (1) | EP2296690B1 (fr) |
JP (5) | JP2011523561A (fr) |
KR (2) | KR101651697B1 (fr) |
CN (1) | CN102143758B (fr) |
AR (1) | AR072009A1 (fr) |
AU (1) | AU2009256232B2 (fr) |
BR (2) | BRPI0911385B8 (fr) |
CA (1) | CA2726589C (fr) |
CL (1) | CL2010001346A1 (fr) |
CO (1) | CO6341566A2 (fr) |
CR (1) | CR11851A (fr) |
EA (3) | EA034847B1 (fr) |
IL (1) | IL209395A (fr) |
JO (1) | JOP20190083A1 (fr) |
MA (1) | MA33142B1 (fr) |
MX (2) | MX346396B (fr) |
MY (1) | MY152721A (fr) |
NZ (1) | NZ590050A (fr) |
PE (1) | PE20100253A1 (fr) |
SG (1) | SG193860A1 (fr) |
TW (2) | TWI526220B (fr) |
WO (1) | WO2009149171A2 (fr) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2068909T3 (da) | 2007-03-30 | 2012-08-06 | Ambrx Inc | Modificerede FGF-21-polypeptider og anvendelse heraf |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
AU2009302318A1 (en) | 2008-10-10 | 2010-04-15 | Amgen Inc. | FGF21 mutants and uses thereof |
WO2010065439A1 (fr) * | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants de facteurde croissance 21 du fibroblaste |
WO2010129600A2 (fr) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Mutants de fgf21 et leurs utilisations |
SG10201402038WA (en) | 2009-05-05 | 2014-07-30 | Amgen Inc | FGF21 Mutants And Uses Thereof |
WO2010148142A1 (fr) | 2009-06-17 | 2010-12-23 | Amgen Inc. | Polypeptides fgf19 chimériques et leurs utilisations |
US8889625B2 (en) * | 2009-07-10 | 2014-11-18 | Northwestern University | Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia |
CN101993485B (zh) * | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
US8372952B2 (en) | 2009-12-02 | 2013-02-12 | Amgen Inc. | Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
WO2011107494A1 (fr) | 2010-03-03 | 2011-09-09 | Sanofi | Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation |
AU2011239689A1 (en) | 2010-04-15 | 2012-11-08 | Amgen Inc. | Human FGF receptor and beta-Klotho binding proteins |
DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
EP2558115B1 (fr) | 2010-04-16 | 2019-07-31 | The Salk Institute for Biological Studies | Procédés de traitement de troubles métaboliques utilisant le fgf |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
WO2012027261A1 (fr) | 2010-08-23 | 2012-03-01 | Amgen Inc. | Dérivés de sulfonylpipérazine qui interagissent avec la protéine régulatrice de la glucokinase pour le traitement du diabète |
CN103282055A (zh) * | 2010-11-05 | 2013-09-04 | CovX科技爱尔兰有限公司 | 抗糖尿病化合物 |
CN102464712A (zh) * | 2010-11-11 | 2012-05-23 | 重庆富进生物医药有限公司 | 缺失型人成纤维细胞生长因子21变异体及其偶联物 |
EP2694491A1 (fr) | 2011-04-05 | 2014-02-12 | Amgen Inc. | Benzodioxépine et composés de benzodioxine qui interagissent avec la protéine régulatrice de la glucokinase pour le traitement du diabète |
US8754044B2 (en) | 2011-05-03 | 2014-06-17 | Northwestern University | Neuroprotection by hepatic cells and hepatocyte secretory factors |
MY163674A (en) | 2011-07-01 | 2017-10-13 | Ngm Biopharmaceuticals Inc | Compositions, uses and method for treatment of metabolic disorders and diseases |
JP2014526441A (ja) * | 2011-08-31 | 2014-10-06 | アムジエン・インコーポレーテツド | 1型糖尿病の治療における使用のためのfgf21 |
EP2567959B1 (fr) | 2011-09-12 | 2014-04-16 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
WO2013037390A1 (fr) | 2011-09-12 | 2013-03-21 | Sanofi | Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase |
US9006400B2 (en) * | 2011-09-26 | 2015-04-14 | Novartis Ag | Fibroblast growth factor-21-Fc fusion proteins |
WO2013045413A1 (fr) | 2011-09-27 | 2013-04-04 | Sanofi | Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase |
AR087973A1 (es) | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
CN102558358A (zh) * | 2011-12-30 | 2012-07-11 | 张海涛 | 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用 |
WO2013123444A1 (fr) | 2012-02-17 | 2013-08-22 | Amgen Inc. | Composés de sulfonyle qui interagissent avec la protéine régulatrice de la glucokinase |
WO2013131091A1 (fr) | 2012-03-02 | 2013-09-06 | New York University | Protéines chimères fgf21 ayant une affinité de liaison augmentée pour le bêta-klotho dans le traitement du diabète de type ii, de l'obésité et des troubles métaboliques apparentés |
WO2013173382A1 (fr) | 2012-05-15 | 2013-11-21 | Amgen Inc. | Benzothiophène sulfonamides et autres composés qui interagissent avec une protéine régulatrice de la glucokinase |
KR102238317B1 (ko) | 2012-05-17 | 2021-04-12 | 익스텐드 바이오사이언시즈, 인크. | 개선된 약물 전달용 캐리어 |
US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
US9474785B2 (en) | 2012-06-07 | 2016-10-25 | New York University | Chimeric fibroblast growth factor 19 proteins and methods of use |
US9464126B2 (en) | 2012-06-07 | 2016-10-11 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子21蛋白質 |
US9422353B2 (en) | 2012-06-11 | 2016-08-23 | Eli Lilly And Company | Fibroblast growth factor 21 variant, composition , and uses thereof |
TW201420606A (zh) * | 2012-08-22 | 2014-06-01 | Lilly Co Eli | 同源二聚體蛋白 |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
EP3798228A1 (fr) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions et procédés pour le traitement de troubles métaboliques et de maladies |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
NZ630469A (en) | 2012-12-27 | 2017-02-24 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US9550820B2 (en) | 2013-02-22 | 2017-01-24 | New York University | Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use |
WO2014149699A1 (fr) | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Protéine bifonctionnelle |
CN103191415A (zh) * | 2013-04-03 | 2013-07-10 | 哈尔滨博翱生物医药技术开发有限公司 | 成纤维细胞生长因子-21成熟肽在制备治疗高血压的药物中的应用 |
WO2015057908A1 (fr) | 2013-10-18 | 2015-04-23 | Novartis Ag | Méthodes de traitement du diabete et de troubles associés |
SG11201603134XA (en) | 2013-10-21 | 2016-05-30 | Salk Inst For Biological Studi | Mutated fibroblast growth factor (fgf) 1 and methods of use |
WO2015061331A1 (fr) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Peptides de facteur de croissance des fibroblastes (fgf) 2/fgf1 chimériques et procédés d'utilisation |
US10369199B2 (en) | 2013-10-28 | 2019-08-06 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of cancer |
PT3097122T (pt) | 2014-01-24 | 2020-07-21 | Ngm Biopharmaceuticals Inc | Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos |
EP3125921B1 (fr) | 2014-03-11 | 2020-07-08 | Novartis AG | Variants de fgf21 pour l'utilisation dans le traitement de la lipodystrophie partielle indue par arv/sida |
WO2015148708A1 (fr) | 2014-03-25 | 2015-10-01 | Regeneron Pharmaceuticals, Inc. | Agonistes du récepteur fgf21 et leurs utilisations |
WO2015183890A2 (fr) * | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Méthodes et compositions pour le traitement de maladies et de troubles métaboliques |
AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
JP6946182B2 (ja) | 2014-10-22 | 2021-10-06 | エクステンド バイオサイエンシズ インコーポレーテッドExtend Biosciences, Inc | 治療用ビタミンdコンジュゲート |
WO2016065052A1 (fr) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Conjugués insuline vitamine d |
RU2729161C2 (ru) | 2014-10-23 | 2020-08-04 | ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. | Фармацевтические композиции, содержащие варианты пептидов, и способы их применения |
US9434778B2 (en) | 2014-10-24 | 2016-09-06 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
TWI708781B (zh) | 2014-12-23 | 2020-11-01 | 丹麥商諾佛 儂迪克股份有限公司 | Fgf21衍生物及其用途 |
KR20160088656A (ko) | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
WO2016187558A2 (fr) | 2015-05-20 | 2016-11-24 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Procédé visant à améliorer l'issue neurologique chez des patients dont la température est modifiée à des fins thérapeutiques |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
KR102670157B1 (ko) * | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
KR102668200B1 (ko) * | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
CA3002400A1 (fr) | 2015-10-30 | 2017-05-04 | Salk Institute For Biological Studies | Traitement de l'hyperglycemie induite par des steroides avec des analogues de facteur de croissance des fibroblastes (fgf) 1 |
AU2016353988B2 (en) | 2015-11-09 | 2019-09-26 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
TW201731867A (zh) | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Fgf21變異體 |
WO2017116207A1 (fr) * | 2015-12-31 | 2017-07-06 | 한미약품 주식회사 | Analogue de fgf21, conjugué de fgf21 et leur utilisation |
US20190142963A1 (en) | 2016-04-15 | 2019-05-16 | Richard D. DiMarchi | Fgf21 c-terminal peptide optimization |
CA3031856A1 (fr) | 2016-08-01 | 2018-02-08 | Peking University | Mutant de mg53, son procede de preparation et ses utilisations |
CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技(上海)有限公司 | 双特异性抗体及其制备方法与用途 |
EP3502143A4 (fr) | 2016-08-19 | 2020-07-15 | Ampsource Biopharma Shanghai Inc. | Peptide de liaison pour la construction d'une protéine de fusion |
CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
AU2017358289A1 (en) | 2016-11-10 | 2019-06-20 | Yuhan Corporation | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins |
KR102657457B1 (ko) | 2016-12-22 | 2024-04-12 | 사노피 | 최적화된 활성 비율을 갖는 fgf21 화합물/glp-1r 작용제 조합물 |
CN108619490A (zh) * | 2017-03-22 | 2018-10-09 | 天士力医药集团股份有限公司 | 一种长效化突变的人源成纤维生长因子的新用途 |
WO2018194413A1 (fr) * | 2017-04-21 | 2018-10-25 | Yuhan Corporation | Procédé de production de protéines à double fonction et ses dérivés |
CN107056925B (zh) * | 2017-04-28 | 2022-01-14 | 中国科学院合肥物质科学研究院 | 人fgf21突变体、其制备方法及用途 |
CA3069143A1 (fr) * | 2017-07-06 | 2019-01-10 | Yale University | Compositions et methodes de traitement ou de prevention de maladies liees au fgf endocrinien |
AU2018329850A1 (en) | 2017-09-08 | 2020-04-23 | Bristol-Myers Squibb Company | Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH) |
CN115109166A (zh) * | 2017-11-24 | 2022-09-27 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多结构域活性蛋白 |
CN111518770B (zh) | 2017-12-19 | 2023-01-06 | 北京吉源生物科技有限公司 | 一种表达glp1和fgf21的干细胞及其用途 |
AU2019218147B2 (en) * | 2018-02-08 | 2023-06-08 | Sunshine Lake Pharma Co., Ltd. | FGF21 variant, fusion protein and application thereof |
SG11202013240RA (en) | 2018-07-03 | 2021-01-28 | Bristol Myers Squibb Co | Fgf21 formulations |
EP3935075A4 (fr) * | 2019-03-05 | 2023-01-18 | Sunshine Lake Pharma Co., Ltd. | Molécule polypeptidique et son application |
US11427623B1 (en) | 2019-05-28 | 2022-08-30 | 89Bio Ltd. | Methods of treatment using mutant FGF-21 peptide conjugates |
US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
AR122359A1 (es) | 2020-01-08 | 2022-09-07 | Bristol Myers Squibb Co | Formulaciones de fgf-21 conjugado |
JP7392491B2 (ja) * | 2020-01-21 | 2023-12-06 | トヨタ自動車株式会社 | 電源システム |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
WO2022032187A1 (fr) | 2020-08-07 | 2022-02-10 | Bristol-Myers Squibb Company | Fgf21 combiné à des antagonistes de ccr2/5 pour le traitement de la fibrose |
US20240123031A1 (en) | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
CN116162145A (zh) | 2021-09-08 | 2023-05-26 | 北京志道生物科技有限公司 | 一种fgf21突变蛋白及其应用 |
CA3233918A1 (fr) | 2021-10-13 | 2023-04-20 | Mariana N. Dimitrova | Compositions pharmaceutiques d'efruxiol |
CN113980147B (zh) * | 2021-11-26 | 2023-07-28 | 中国药科大学 | 一种聚多肽与fgf21融合蛋白突变体及其应用 |
WO2023173021A2 (fr) * | 2022-03-11 | 2023-09-14 | The Board Of Regents Of The University Of Texas System | Méthodes et compositions de traitement de la toxicité d'alcool |
WO2024059507A1 (fr) | 2022-09-12 | 2024-03-21 | Akero Therapeutics, Inc. | Polypeptides mutants de fgf21 |
Family Cites Families (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4436366A (en) | 1981-02-17 | 1984-03-13 | E. I. Du Pont De Nemours And Company | End capping an optical fiber |
AR230173A1 (es) | 1981-06-29 | 1984-03-01 | American Cyanamid Co | Instrumento para ligaciones quirurgicas |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
EP0088046B1 (fr) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipides en phase aqueuse |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3478642D1 (en) | 1983-07-29 | 1989-07-13 | Mitsubishi Electric Corp | Solid state overcurrent detector |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0154316B1 (fr) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Lymphokine chimiquement modifiée et son procédé de préparation |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
CA1310924C (fr) | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Systeme d'administration d'un medicament a l'aide de particules infectieuses |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4970154A (en) | 1987-10-09 | 1990-11-13 | Baylor College Of Medicine | Method for inserting foreign genes into cells using pulsed radiofrequency |
EP0315456B1 (fr) | 1987-11-05 | 1994-06-01 | Hybritech Incorporated | Immunoglobulines modifiées au moyen d'un polysaccharide présentant un potentiel immunogène réduit ou des cinétiques pharmacologiques améliorées |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
CA2006596C (fr) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | G-csf modifie chimiquement |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5288855A (en) * | 1989-01-23 | 1994-02-22 | Farmitalia Carlo Erba | Extracellular form of the human fibroblast growth factor receptor |
ATE179862T1 (de) | 1989-07-06 | 1999-05-15 | Univ California | Rezeptoren für fibroblasten-wachstumsfaktoren |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
EP0505500B1 (fr) | 1989-12-22 | 1997-07-30 | Applied Research Systems Ars Holding N.V. | Modification de l'expression de genes endogenes a l'aide d'un element regulateur par recombinaison homologue |
WO1991010470A1 (fr) | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Dispositifs et procedes d'apport ameliore de facteurs actifs |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5672510A (en) | 1990-01-19 | 1997-09-30 | Genetic Therapy, Inc. | Retroviral vectors |
CA2086425C (fr) | 1990-07-06 | 2006-01-17 | Craig A. Dionne | Recepteurs de facteurs de croissance des fibroblastes |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5217889A (en) | 1990-10-19 | 1993-06-08 | Roninson Igor B | Methods and applications for efficient genetic suppressor elements |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5229501A (en) * | 1991-01-11 | 1993-07-20 | Chiron Corporation | Expression and use of human fibroblast growth factor receptor |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
IL100219A0 (en) | 1991-12-02 | 1992-09-06 | Yeda Res & Dev | Variable region within fibroblast growth factor receptors that confers ligand specificity |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
US5364791A (en) | 1992-05-14 | 1994-11-15 | Elisabetta Vegeto | Progesterone receptor having C. terminal hormone binding domain truncations |
AU686566B2 (en) * | 1992-06-18 | 1998-02-12 | Whittier Institute For Diabetes And Endocrinology, The | Process for detection of neoplastic disease |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
US5474914A (en) | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
US5489743A (en) | 1993-01-19 | 1996-02-06 | Amgen Inc. | Transgenic animal models for thrombocytopenia |
US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
JPH11501201A (ja) | 1993-05-07 | 1999-02-02 | スターリング ウィンスロップ インコーポレイティド | ラクトース加水分解牛乳及び味を改善し甘味を抑えた乳製品 |
AU6760794A (en) | 1993-05-26 | 1994-12-20 | Ontario Cancer Institute, The | Transgenic mammals lacking expression of particular cd45 isoforms |
US6664107B1 (en) | 1993-05-26 | 2003-12-16 | Ontario Cancer Institute, University Health Network | CD45 disrupted nucleic acid |
US5654168A (en) | 1994-07-01 | 1997-08-05 | Basf Aktiengesellschaft | Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units |
WO1994029442A2 (fr) | 1993-06-14 | 1994-12-22 | Basf Aktiengesellschaft | Maitrise precise de l'expression des genes dans les cellules encaryotes au moyen de promoteurs reagissant a la tetracycline |
US5589362A (en) | 1993-06-14 | 1996-12-31 | Basf Aktiengesellschaft | Tetracycline regulated transcriptional modulators with altered DNA binding specificities |
AU7568094A (en) | 1993-08-12 | 1995-03-14 | Cytotherapeutics, Inc. | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5484720A (en) | 1994-09-08 | 1996-01-16 | Genentech, Inc. | Methods for calcium phosphate transfection |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
EP1978033A3 (fr) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Anticorps humains dérivés à partir de xénosouris immunisée |
PL323587A1 (en) | 1995-05-26 | 1998-04-14 | Zeneca Ltd | Gene changing-over system including edisone receptor |
US5849303A (en) | 1995-06-07 | 1998-12-15 | American Home Products Corporation | Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection |
EP0832269A1 (fr) | 1995-06-07 | 1998-04-01 | Baylor College Of Medicine | Transporteurs d'acide nucleique servant a introduire des acides nucleiques dans une cellule |
KR19990022651A (ko) | 1995-06-07 | 1999-03-25 | 데이비드 엘. 버스테인 | 생물학적 사건에 대한 라파마이신 기재 조절방법 |
ATE465149T1 (de) | 1996-02-28 | 2010-05-15 | Ariad Pharma Inc | Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen |
AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US5679559A (en) | 1996-07-03 | 1997-10-21 | University Of Utah Research Foundation | Cationic polymer and lipoprotein-containing system for gene delivery |
US6214795B1 (en) * | 1996-11-12 | 2001-04-10 | Praecis Pharmaceuticals, Inc. | Peptide compounds useful for modulating FGF receptor activity |
KR20000062345A (ko) | 1996-12-26 | 2000-10-25 | 히라타 다다시 | 신규 폴리펩타이드, 신규 dna 및 신규 항체 |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
NZ504425A (en) | 1997-11-25 | 2001-10-26 | Genentech Inc | Nucleic acid molecules and polypeptides of fibroblast growth factor-19 (PRO533) |
US6150098A (en) | 1998-02-20 | 2000-11-21 | Amgen Inc. | Methods for identifying novel secreted mammalian polypeptides |
ZA200007412B (en) | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
NL1010174C1 (nl) | 1998-09-24 | 2000-03-27 | Busschers Metaalbedrijf Bv | Inrichting en werkwijze voor het buigen van buisvormig en staafvormig materiaal. |
US6548634B1 (en) | 1998-09-30 | 2003-04-15 | Chiron Corporation | Synthetic peptides having FGF receptor affinity |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6369109B1 (en) | 1998-10-28 | 2002-04-09 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumor |
WO2000027885A1 (fr) | 1998-11-05 | 2000-05-18 | Kyowa Hakko Kogyo Co., Ltd. | Nouveau popypeptide chimerique |
AU3224700A (en) | 1999-02-08 | 2000-08-25 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
EP1183051A2 (fr) | 1999-03-15 | 2002-03-06 | Chiron Corporation | Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la pr vention des maladies de l'oeil |
CA2311201A1 (fr) | 1999-08-05 | 2001-02-05 | Genset S.A. | Sequences marqueurs exprimees et proteines humaines codees |
US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US7408047B1 (en) | 1999-09-07 | 2008-08-05 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
WO2001018209A1 (fr) | 1999-09-10 | 2001-03-15 | Curagen Corporation | Polypeptides du facteur de croissance du fibroblaste et acides nucleiques les codant |
WO2001032678A1 (fr) | 1999-11-05 | 2001-05-10 | Smithkline Beecham Corporation | sbgFGF-19a |
US6254671B1 (en) | 1999-11-15 | 2001-07-03 | Engelhard Corporation | Very green-shade yellow metallized disazo pigment |
AU1922101A (en) | 1999-11-18 | 2001-05-30 | Chiron Corporation | Human fgf-21 gene and gene expression products |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
AU1628101A (en) | 1999-11-22 | 2001-06-04 | Millennium Pharmaceuticals, Inc. | Jaffa, a novel fibroblast growth factor family member and uses therefor |
US7108984B2 (en) | 2000-01-12 | 2006-09-19 | Mount Sinai School Of Medicine | Methods of identifying modulators of the FGF receptor |
US20020081663A1 (en) | 2000-01-05 | 2002-06-27 | Conklin Darrell C. | Novel FGF homolog ZFGF11 |
AU2631001A (en) | 2000-01-05 | 2001-07-16 | Zymogenetics Inc. | Novel fgf homolog zfgf11 |
US20020001825A1 (en) | 2000-03-31 | 2002-01-03 | Nobuyuki Itoh | Fibroblast growth factor-like molecules and uses thereof |
JP2002112772A (ja) | 2000-07-10 | 2002-04-16 | Takeda Chem Ind Ltd | 新規ポリペプチドおよびそのdna |
IL139380A0 (en) | 2000-10-31 | 2001-11-25 | Prochon Biotech Ltd | Active variants of fibroblast growth factor |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
US20060223114A1 (en) | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
US20040018499A1 (en) | 2001-06-06 | 2004-01-29 | Lal Preeti G | Extracellular messengers |
IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
AU2002325819B2 (en) | 2001-07-11 | 2008-06-19 | Maxygen, Inc. | G-CSF Conjugates |
WO2003011213A2 (fr) | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Methode de traitement du diabete et de l'obesite |
WO2003038054A2 (fr) | 2001-10-31 | 2003-05-08 | New York University | Conception et synthese de type structurel d'inhibiteurs de facteur de croissance fibroblastique (fgf), et composes modulateurs de fgf |
WO2003059270A2 (fr) | 2002-01-15 | 2003-07-24 | Eli Lilly And Company | Methode de diminution de la morbidite et de la mortalite chez des patients gravement malades |
EP1332761A1 (fr) | 2002-01-31 | 2003-08-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Agonistes des récepteurs du facteur de croissance des fibroblastes |
JP2005530687A (ja) | 2002-01-31 | 2005-10-13 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | Fgfrアゴニスト |
IL149562A0 (en) | 2002-05-09 | 2002-11-10 | Prochon Ltd | Fgf variants and methods for use thereof |
JP2003334088A (ja) | 2002-05-22 | 2003-11-25 | Pharma Design Inc | ヒト由来の新規Klotho様タンパク質及びその遺伝子 |
WO2004022095A1 (fr) | 2002-09-04 | 2004-03-18 | Abtech | Anticorps anti-idiotypiques utiles en tant qu'agonistes d'un recepteur vegf ou fgf pour la therapie osseuse |
US20060263774A1 (en) | 2002-11-01 | 2006-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
CA2510715A1 (fr) | 2002-12-20 | 2004-07-08 | Enkam Pharmaceuticals A/S | Methode de modulation de l'interaction d'un recepteur et d'un ligand |
TWI300430B (en) | 2003-01-10 | 2008-09-01 | Ritek Corp | Optical recording medium dye and optical recording medium using thereof |
WO2004083381A2 (fr) | 2003-03-13 | 2004-09-30 | Indiana University Advanced Research & Technology Institute | Polynucleotides, polypeptides et mutants des recepteurs 1 du facteur de croissance des fibroblastes |
JP2006240990A (ja) | 2003-05-15 | 2006-09-14 | Kirin Brewery Co Ltd | klothoタンパク質および抗klothoタンパク質抗体ならびにそれらの用途 |
ES2298785T3 (es) | 2003-06-12 | 2008-05-16 | Eli Lilly And Company | Proteinas de fusion. |
ATE525395T1 (de) | 2003-06-12 | 2011-10-15 | Lilly Co Eli | Fusions proteine von glp-1-analoga |
WO2005019258A2 (fr) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions et methodes de traitement de maladies relatives au systeme immunitaire |
JP4049723B2 (ja) | 2003-09-04 | 2008-02-20 | 沖電気工業株式会社 | 窒化物半導体素子の製造方法及び窒化物半導体素子の製造装置 |
US20070274981A1 (en) | 2003-10-16 | 2007-11-29 | Imclone Systems Incorporation | Fibroblast Growth Factor Receptor-1 Inhibitors and Methods of Treatment Thereof |
AU2004303783A1 (en) * | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
EP1697420A2 (fr) | 2003-12-19 | 2006-09-06 | Five Prime Therapeutics, Inc. | Utilisation des recepteurs 1, 2, 3 et 4 du facteur de croissance des fibroblastes comme cibles pour une intervention therapeutique |
US20090111742A1 (en) | 2004-01-26 | 2009-04-30 | Alexei Kharitonenkov | Use of fgf-21 and thiazolidinedione for treating type 2 diabetes |
US20070265200A1 (en) | 2004-03-17 | 2007-11-15 | Eli Lilly And Company | Glycol Linked Fgf-21 Compounds |
JP4505631B2 (ja) | 2004-03-31 | 2010-07-21 | 独立行政法人産業技術総合研究所 | ヘパラン硫酸糖鎖を付加したヘパリン結合性タンパク質、その製造方法及びそれを含有する医薬組成物 |
PL1751184T3 (pl) | 2004-05-13 | 2010-02-26 | Lilly Co Eli | Białka fuzyjne FGF-21 |
CA2575753A1 (fr) * | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteines de facteur de croissance 21 de fibroblaste |
US7622445B2 (en) | 2004-09-02 | 2009-11-24 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
EP1796709A4 (fr) | 2004-10-07 | 2009-10-28 | Univ California | Analogues de la toxine shk et utilisations dans l'inhibition selective des canaux potassiques kv1.3 |
EP3061461A1 (fr) | 2004-10-29 | 2016-08-31 | ratiopharm GmbH | Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf) |
US7655627B2 (en) | 2004-12-14 | 2010-02-02 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
US20080261875A1 (en) | 2005-01-21 | 2008-10-23 | Eli Lilly And Company | Method For Treating Cardiovascular Disease |
US20060193299A1 (en) * | 2005-02-25 | 2006-08-31 | Cicso Technology, Inc., A California Corporation | Location-based enhancements for wireless intrusion detection |
JP2006246823A (ja) | 2005-03-11 | 2006-09-21 | Kyoto Univ | 造血因子としてのFgf21の使用 |
WO2006130527A2 (fr) | 2005-05-31 | 2006-12-07 | Novartis Ag | Mutations et polymorphismes de recepteur du facteur de croissance 1 des fibroblastes |
EP2083081A1 (fr) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions et procédés pour traiter une maladie avec des protéines de fusion FGFR |
JP2009504183A (ja) | 2005-08-15 | 2009-02-05 | ジェネンテック・インコーポレーテッド | 遺伝子破壊、それに関連する組成物および方法 |
US7395962B2 (en) | 2005-10-28 | 2008-07-08 | United Parcel Service Of America, Inc. | Pick up notice and method of using same |
US8043833B2 (en) | 2005-10-31 | 2011-10-25 | Novo Nordisk A/S | Expression of soluble therapeutic proteins |
WO2007056789A1 (fr) | 2005-11-16 | 2007-05-24 | Dier Corporation As Trustee For The Reid Family Superannuation Trust | Nouveaux ensembles de cadres sur écrans de sécurité |
EP1996215A2 (fr) | 2006-02-28 | 2008-12-03 | Trustees Of Boston University | Régulateurs métaboliques et leurs utilisations |
WO2007110079A2 (fr) * | 2006-03-29 | 2007-10-04 | Enkam Pharmaceuticals A/S | Administration ciblée de ligands du récepteur fgrf au cerveau |
US8101721B2 (en) | 2006-06-15 | 2012-01-24 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | ポリペプチドコンジュゲートの精製方法 |
WO2008066498A1 (fr) | 2006-12-01 | 2008-06-05 | Agency For Science, Technology And Research | Protéine kinases liées au cancer |
DK2068909T3 (da) | 2007-03-30 | 2012-08-06 | Ambrx Inc | Modificerede FGF-21-polypeptider og anvendelse heraf |
ES2665996T3 (es) | 2007-04-02 | 2018-04-30 | Genentech, Inc. | Anticuerpo agonista de klotho-beta para utilizar en el tratamiento de diabetes mellitus o resistencia a la insulina |
US8697369B2 (en) | 2007-04-06 | 2014-04-15 | National Institute Of Advanced Industrial Science And Technology | Method for screening a test substance for activating a receptor associated with FGF 21 activity |
US7537903B2 (en) | 2007-04-23 | 2009-05-26 | Board Of Regents, The University Of Texas System | FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner |
WO2008135993A1 (fr) | 2007-05-08 | 2008-11-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Protéine klotho et composés apparentés destinés au traitement et au diagnostic du cancer |
MX2009012625A (es) | 2007-05-22 | 2009-12-07 | Novartis Ag | Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21. |
CA2689242C (fr) | 2007-05-29 | 2015-07-07 | Kohzoh Imai | Agent et procede pour le traitement du cancer |
EP2162535A4 (fr) | 2007-06-04 | 2011-02-23 | Novo Nordisk As | Glycosylation à liaisons o utilisant des n-acétylglucosaminyl transférases |
US20110034373A1 (en) | 2007-08-03 | 2011-02-10 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
GB2464062A (en) | 2007-08-08 | 2010-04-07 | Foster Miller Inc | Watercraft drogue system |
US8426396B2 (en) | 2008-01-08 | 2013-04-23 | Shriners Hospitals For Children | Treatment for achondroplasia |
TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
US20110015345A1 (en) | 2008-03-19 | 2011-01-20 | Ambrx, Inc. | Modified FGF-23 Polypeptides and Their Uses |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
WO2010006214A1 (fr) | 2008-07-09 | 2010-01-14 | Ambrx, Inc. | Anticorps de neutralisation de fgf-21 et leurs utilisations |
US8338569B2 (en) | 2008-08-04 | 2012-12-25 | Five Prime Therapeutics, Inc. | FGFR extracellular domain acidic region muteins |
AU2009302318A1 (en) * | 2008-10-10 | 2010-04-15 | Amgen Inc. | FGF21 mutants and uses thereof |
WO2010129600A2 (fr) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Mutants de fgf21 et leurs utilisations |
SG10201402038WA (en) | 2009-05-05 | 2014-07-30 | Amgen Inc | FGF21 Mutants And Uses Thereof |
WO2010148142A1 (fr) | 2009-06-17 | 2010-12-23 | Amgen Inc. | Polypeptides fgf19 chimériques et leurs utilisations |
BR112012008907A2 (pt) | 2009-10-15 | 2020-11-24 | Genentech, Inc | fatores de crescimento de fibroblastos quiméricos com especificidade receptora alterada |
US8372952B2 (en) | 2009-12-02 | 2013-02-12 | Amgen Inc. | Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
AU2011239689A1 (en) | 2010-04-15 | 2012-11-08 | Amgen Inc. | Human FGF receptor and beta-Klotho binding proteins |
US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
MY163674A (en) | 2011-07-01 | 2017-10-13 | Ngm Biopharmaceuticals Inc | Compositions, uses and method for treatment of metabolic disorders and diseases |
EP2548570A1 (fr) | 2011-07-19 | 2013-01-23 | Sanofi | Composition pharmaceutique pour le traitement d'un syndrome métabolique |
JP2014526441A (ja) * | 2011-08-31 | 2014-10-06 | アムジエン・インコーポレーテツド | 1型糖尿病の治療における使用のためのfgf21 |
NZ630469A (en) | 2012-12-27 | 2017-02-24 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
-
2008
- 2008-06-04 JO JOP/2019/0083A patent/JOP20190083A1/ar unknown
-
2009
- 2009-06-03 SG SG2013067194A patent/SG193860A1/en unknown
- 2009-06-03 KR KR1020117000029A patent/KR101651697B1/ko active IP Right Grant
- 2009-06-03 EA EA201690946A patent/EA034847B1/ru unknown
- 2009-06-03 EP EP09759330.5A patent/EP2296690B1/fr active Active
- 2009-06-03 CN CN200980130476.4A patent/CN102143758B/zh active Active
- 2009-06-03 MX MX2012002985A patent/MX346396B/es unknown
- 2009-06-03 WO PCT/US2009/046113 patent/WO2009149171A2/fr active Application Filing
- 2009-06-03 JP JP2011512611A patent/JP2011523561A/ja active Pending
- 2009-06-03 MA MA34197A patent/MA33142B1/fr unknown
- 2009-06-03 CA CA2726589A patent/CA2726589C/fr active Active
- 2009-06-03 NZ NZ590050A patent/NZ590050A/xx unknown
- 2009-06-03 MY MYPI20105725 patent/MY152721A/en unknown
- 2009-06-03 BR BRPI0911385A patent/BRPI0911385B8/pt active IP Right Grant
- 2009-06-03 AU AU2009256232A patent/AU2009256232B2/en active Active
- 2009-06-03 US US12/455,610 patent/US8034770B2/en active Active
- 2009-06-03 KR KR1020167010524A patent/KR101787300B1/ko active IP Right Grant
- 2009-06-03 BR BR122020010972-6A patent/BR122020010972B1/pt active IP Right Grant
- 2009-06-03 MX MX2010013333A patent/MX2010013333A/es active IP Right Grant
- 2009-06-03 EA EA201001883A patent/EA017690B1/ru not_active IP Right Cessation
- 2009-06-03 EA EA201270758A patent/EA024751B8/ru not_active IP Right Cessation
- 2009-06-04 AR ARP090102008A patent/AR072009A1/es active IP Right Grant
- 2009-06-04 TW TW100144484A patent/TWI526220B/zh active
- 2009-06-04 PE PE2009000781A patent/PE20100253A1/es active IP Right Grant
- 2009-06-04 TW TW098118662A patent/TWI403519B/zh active
-
2010
- 2010-11-17 IL IL209395A patent/IL209395A/en active IP Right Grant
- 2010-12-03 CL CL2010001346A patent/CL2010001346A1/es unknown
- 2010-12-16 CR CR11851A patent/CR11851A/es unknown
- 2010-12-30 CO CO10164989A patent/CO6341566A2/es active IP Right Grant
-
2011
- 2011-08-02 US US13/196,544 patent/US8410051B2/en active Active
- 2011-12-15 US US13/327,504 patent/US8642546B2/en active Active
- 2011-12-16 US US13/328,028 patent/US8361963B2/en active Active
-
2013
- 2013-12-19 US US14/134,482 patent/US9273106B2/en active Active
-
2016
- 2016-01-12 JP JP2016003404A patent/JP6250714B2/ja active Active
- 2016-01-22 US US15/004,281 patent/US10011642B2/en active Active
-
2017
- 2017-11-21 JP JP2017223339A patent/JP6960832B2/ja active Active
-
2018
- 2018-06-01 US US15/996,232 patent/US11072640B2/en active Active
-
2019
- 2019-04-26 JP JP2019085051A patent/JP6810190B2/ja active Active
-
2020
- 2020-12-09 JP JP2020204106A patent/JP7191076B2/ja active Active
-
2021
- 2021-06-24 US US17/357,444 patent/US11840558B2/en active Active
-
2023
- 2023-11-01 US US18/499,499 patent/US20240076333A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33142B1 (fr) | Mutants fgf21 et leurs utilisations | |
MA33716B1 (fr) | Mutants de fgf21 et leurs utilisations | |
MA32771B1 (fr) | Mutants fgf21 et leurs utilisations | |
MA31764B1 (fr) | Composés et compositions en tant que modulateurs de l'activité de gpr119 | |
WO2010129600A3 (fr) | Mutants de fgf21 et leurs utilisations | |
MA33279B1 (fr) | Compositions et procédés pour l'augmentation de la croissance des muscles | |
EP3552607A3 (fr) | Inhibiteurs de syk d'imidazopyrazine | |
FR13C0062I2 (fr) | Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques | |
MX2011006091A (es) | Inhibidores de imidazopirazina syk. | |
BRPI0413326A (pt) | métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel | |
MA30337B1 (fr) | Anticorps | |
HK1145628A1 (en) | Pharmaceutical compositions having an analgesic effect and containing 1- benzyl-1-hydroxy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino propionic acid amides or related compounds | |
MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
FR2868784A1 (fr) | Copolymere sequence, composition le comprenant et procede de traitement cosmetique | |
TW200716172A (en) | Pharmaceutical compositions for treating lower motor neuron diseases | |
NZ584642A (en) | Factor involved in latent infection with herpesvirus, and use thereof | |
TW200735868A (en) | Compositions and methods for treating CNS disorders | |
MA29723B1 (fr) | Composes | |
WO2003016563A3 (fr) | Cible moleculaire de la neurotoxicite | |
TW200740441A (en) | Methods and reagents for the treatment of inflammatory disorders | |
FR2883181B1 (fr) | Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee | |
FR2941152B1 (fr) | Vecteurs comprenant une macromolecule anionique et un lipide cationique pour l'administration de petits acides nucleiques. | |
DE602004009068D1 (de) | Glycosaminoglykane zur behandlung emotionaler störungen | |
TN2010000563A1 (en) | Fgf 21 mutants and uses thereof | |
FR2906470B1 (fr) | Utilisation de la 6'-ethyl-lepimectine, la 6'-methyl-lepimectine ou leurs derives pour le traitement de desordres dermatologiques chez l'homme |